

VEQ 360°



Una risorsa indispensabile per confermare e migliorare la qualità di tutto il tuo laboratorio.

Catalogo 2025

LABQUALITY

Microbiologia e Virologia

Product Catalogue 2025

3 Updates for 2025

4 Microbiology

4	Bacterial Serology
5	Bacteriology
9	Mycology
9	Parasitology
10	Virology

15 Nucleic acid detection

16 Multiplex

17 Point-of-Care

Updates for 2025

New schemes and products

- 5850 *Brucella* antibodies
- 5687 HBsAg and HCVA_b POCT
- 5251 Interferon Gamma Release Assay (IGRA) for *Mycobacterium tuberculosis* - whole blood sample
- 5686 Norovirus, antigen detection

Changes in distribution schedule

- 5682 Hepatitis E, antibodies (April and October)
- 5636 Zika virus, antibodies (April and October)
- 5300 Respiratory infections multiplex, nucleic acid detection (February, May, September and November)
- 5304 Gastrointestinal viral multiplex, nucleic acid detection (4 rounds/year)
- 5254 *Mycoplasma genitalium*, drug resistance, nucleic acid detection (4 rounds/year)
- 5651 CMV and EBV, nucleic acid detection, quantitative (March and October)

2025 Planned pilot schemes

Pilot studies are EQA schemes under development. Information about pilot studies and schedules are updated on our website:
<https://www.labquality.com/external-quality-assessment/new-schemes/>

Microbiology

The microbiological EQA programs are suitable for clinical laboratories and POCT sites performing testing in the areas of **bacterial serology, bacteriology, mycology, parasitology and virology**. While the selection includes schemes for antigen detection, antibody detection, culture, microscopy, and PCR tests, solutions for versatile needs are available. Authentic single donor samples are included in multiple schemes.

Microbiology » Bacterial Serology

Test ID	Test Name	Specimens	Performance across 12 sites (1 = best, 12 = worst)												Notes
			1	2	3	4	5	6	7	8	9	10	11	12	
5840	Antistreptolysin	2 liquid human serum or plasma samples, 0.4 mL. Authentic, commutable, single donor samples.	3		●			●			●				
5950	<i>Bordetella pertussis</i> , antibodies	2 liquid human serum samples, 0.3 mL.	3	●			●			●			●		
5960	<i>Borrelia burgdorferi</i> , antibodies, European origin	2 liquid human serum or plasma samples, 0.5 mL. Authentic, commutable, single donor samples.	3	●			●			●			●		
5850	<i>Brucella</i> antibodies	2 liquid human serum or plasma samples, 0.5 mL each.	3			●						●			
5965	CXCL 13 Chemokine	2 liquid samples.	3	●			●			●		●			
5620	<i>Chlamydia pneumoniae</i> , antibodies	3 liquid serum or plasma samples, 0.4 mL.	3		●			●			●			●	
5851	<i>Francisella tularensis</i> , antibodies	3 liquid human serum or plasma samples, 0.5 mL.	3			●					●				
5860	<i>Helicobacter pylori</i> , antibodies	2 liquid human serum or plasma samples, 0.4 mL. Examinations: <i>H. pylori</i> IgA, IgG and total antibodies, quantitative and qualitative tests, post-analytical clinical interpretation.	3			●					●			●	

5980 *Mycoplasma pneumoniae*, antibodies

③

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 liquid human serum or plasma samples, 0.3 mL.
Authentic, commutable, single donor samples.

Examinations: *M. pneumoniae* IgG, IgM and total antibodies, post-analytical clinical interpretation.

Notes: For clinical laboratories and POCT sites.

5880 Syphilis serology

③

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 liquid human serum samples, 0.6 mL.
Authentic, commutable, single donor samples.

Examinations: Cardiolipin, *Treponema pallidum* antibodies, post-analytical clinical interpretation.

Microbiology » Bacteriology**5050** Bacteriological staining, direct

③

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 3 cases, 3–9 digital images.

Examinations: Interpretation of digital images taken from direct bacteriological Gram staining of clinical samples.

5100 Blood culture (incl. sepsis multiplex methods)

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 3 lyophilised samples. Brief case histories also given. Fresh blood is needed in the specimen preparation. The samples intended for susceptibility testing may include both international quality control strains and clinical strains.

Examinations: Culture, identification, antimicrobial susceptibility testing. Direct nucleic acid detection from positive blood culture bottles by multiplex methods is included in the scheme.

Notes: Fresh blood is needed but not included in the shipment.

5101 Blood culture, screening (incl. sepsis multiplex methods)

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 3 lyophilised samples. Brief case histories also given. Fresh blood is needed in the specimen preparation.

Notes: Fresh blood is needed but not included in the shipment.

Examinations: Culture, preliminary identification using Gram staining and/or direct nucleic acid detection from positive blood culture bottles by multiplex methods. The scheme is also suitable for stem cell banks screening only for possible growth.

5150 Cerebrospinal fluid, bacterial culture

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 lyophilised samples. Brief case histories are also given.

Notes: See also scheme 5303 *Meningitis encephalitis* multiplex, nucleic acid detection.

Examinations: Culture and identification. The scheme is also suitable for laboratories performing screening and reporting merely a preliminary identification.

5612 *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, nucleic acid detection

③

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 3 simulated swab/urine samples, 2 mL.

Notes: See also scheme 5302 Sexually transmitted diseases multiplex, nucleic acid detection. The samples contain hDNA.

Examinations: Detection of *C. trachomatis* and *N. gonorrhoeae* nucleic acid.

5200 *Clostridioides difficile*, culture and toxin detection

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 lyophilised mixtures of bacteria.

Examinations: This scheme includes *C. difficile* culture, antigen detection (GDH), toxin detection and direct nucleic acid detection. Hypervirulent *C. difficile* strains also included.

5202 <i>Clostridioides difficile</i> , extra set of samples	1	2	3	4	5	6	7	8	9	10	11	12
---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 lyophilised mixtures of bacteria.

Notes: Only in connection with scheme 5200.

5201 <i>Clostridioides difficile</i> , nucleic acid detection	1	2	3	4	5	6	7	8	9	10	11	12
---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 lyophilised mixtures of bacteria.

Examinations: *C. difficile* direct nucleic acid detection. Hypervirulent *C. difficile* strains also included.

Notes: 5200 includes also this examination

5191 Faecal bacterial pathogens multiplex, nucleic acid detection	1	2	3	4	5	6	7	8	9	10	11	12
---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 3 samples. Either lyophilised mixtures of bacteria and/or simulated samples, 1 mL.

Examinations: Direct nucleic acid detection. Pathogens included are *Aeromonas*, *Campylobacter*, *E. coli* EHEC (stx1/stx2), *E. coli* EAEC, *E. coli*

EIEC, *E. coli* EPEC, *E. coli* ETEC, *Plesiomonas*, *Salmonella*, *Shigella* and *Yersinia*.

Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5190 Faecal culture	1	2	3	4	5	6	7	8	9	10	11	12
---------------------	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 lyophilised mixtures of bacteria.

Examinations: Culture, identification and antimicrobial susceptibility (rounds 2 and 4). In addition to culture, samples are also suitable for

direct nucleic acid detection. Pathogens included are *Aeromonas*, *Campylobacter*, *Plesiomonas*, *Salmonella*, *Shigella* and *Yersinia*.

5080 General Bacteriology 1 (aerobes and anaerobes)	1	2	3	4	5	6	7	8	9	10	11	12
---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 4 lyophilised mixtures of microbes: both pathogens and normal flora. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical cases.

Notes: 5080 includes 5081, General Bacteriology 2.

EQAS³

5081 General Bacteriology 2 (aerobes)	1	2	3	4	5	6	7	8	9	10	11	12
---------------------------------------	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 lyophilised mixtures of microbes: both pathogens and normal flora. The specimens intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical cases.

Notes: 5080 General Bacteriology 1 includes 5081.

EQAS³

5041 Gram stain, blood culture	1	2	3	4	5	6	7	8	9	10	11	12
--------------------------------	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 air-dried, unfixed microbe suspensions on slides. Brief case histories also given.

Examinations: Staining and microscopy.

5040 Gram stain, colonies	1	2	3	4	5	6	7	8	9	10	11	12
---------------------------	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 3 air-dried, unfixed microbe suspensions on a slide.

Examinations: Staining and microscopy.

5596 <i>Helicobacter pylori</i> , antigen detection in faeces	1	2	3	4	5	6	7	8	9	10	11	12
---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 3 samples: lyophilised faecal.

Examinations: Antigen detection.

Notes: For clinical laboratories and POCT sites.

POCT

5253 <i>Helicobacter pylori</i> , drug resistance, nucleic acid detection	1	2	3	4	5	6	7	8	9	10	11	12
---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 3 simulated swab samples.

Examinations: *H. pylori* nucleic acid detection, clarithromycin susceptibility.

Notes: The samples are suitable for all *H. pylori* NAT methods.

5597 Legionella, antigen detection in urine

③

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 3 simulated urine samples.

Examinations: Legionella antigen detection.

5230 *Mycobacterium tuberculosis*, drug resistance, nucleic acid detection

③

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 simulated samples, 1 mL.

Examinations: *Mycobacterium tuberculosis* nucleic acid detection, rifampicin susceptibility and isoniazid susceptibility.5231 *Mycobacterium tuberculosis*, drug resistance, nucleic acid detection, extra set of samples

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 simulated samples, 1 mL.

Notes: Only in connection with scheme 5230.

5220 Mycobacterial culture and stain

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 lyophilized samples and 2 fixed smears on slides.

Notes: See also products 5250 and 5251 IGRA for *M. tuberculosis*.Examinations: Detection of *Mycobacterium tuberculosis*, *Mycobacterium tuberculosis* complex and atypical mycobacteria: culture, direct nucleic acid detection, acid-fast staining and microscopy.

5221 Mycobacterial nucleic acid detection

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 lyophilized samples.

Notes: 5220 includes also this examination. For additional set of samples, order scheme 5222.

5222 Mycobacteria, extra set of samples

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 lyophilized samples.

Notes: Only in connection with scheme 5220 or 5221.

5240 Mycobacterial stain

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 fixed smears on slides.

Examinations: Acid-fast staining and microscopy.

5254 *Mycoplasma genitalium*, drug resistance, nucleic acid detection

③

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 3 simulated swab samples.

Notes: The samples are suitable for all *M. genitalium* NAT methods and primarily intended for methods detecting point mutations causing macrolide resistance. The samples contain hDNA.5120 *Neisseria gonorrhoeae* (Gc), culture and susceptibility testing

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 lyophilised mixtures of microbes. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains.

Examinations: Culture, identification and antimicrobial susceptibility testing. Also suitable for laboratories performing preliminary screening.

5180 *Salmonella* culture

①

1 2 3 4 5 6 7 8 9 10 11 12

Specimens: 2 lyophilised mixtures of bacteria. Examinations: Culture.

Notes: 5190 also includes 5180.

5599 <i>Streptococcus agalactiae</i> (GBS), nucleic acid detection	3	1 2 3 4 5 6 7 8 9 10 11 12	POCT
Specimens: 2 swab samples. Samples also include normal flora.			
Examinations: Direct nucleic acid detection.			
Notes: The samples contain hDNA. See also product 5594 for <i>S. agalactiae</i> (GBS) culture.			
5594 <i>Streptococcus agalactiae</i> (GBS), culture	1	1 2 3 4 5 6 7 8 9 10 11 12	
Specimens: 2 lyophilised samples. Samples include pathogens and/or normal flora.			
Examinations: Culture.			
Notes: See also product 5599 for direct nucleic acid detection.			
5598 <i>Streptococcus pneumoniae</i> , antigen detection in urine	3	1 2 3 4 5 6 7 8 9 10 11 12	POCT
Specimens: 3 simulated urine specimens.			
Examinations: <i>S. pneumoniae</i> antigen detection.			
Notes:			
5595 <i>Streptococcus pyogenes</i> (Group A), antigen detection in pharyngeal sample	3	1 2 3 4 5 6 7 8 9 10 11 12	POCT
Specimens: 3 simulated pharyngeal samples.			
Examinations: Antigen detection.			
Notes: For clinical laboratories and POCT sites.			
5593 <i>Streptococcus pyogenes</i> (Group A), nucleic acid detection in pharyngeal sample	3	1 2 3 4 5 6 7 8 9 10 11 12	POCT
Specimens: 3 simulated pharyngeal samples.			
Examinations: Nucleic acid detection.			
Notes:			
5073 Surveillance for multidrug resistant bacteria, gramnegative rods	1	1 2 3 4 5 6 7 8 9 10 11 12	
Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.			
Examinations: The scheme is intended for laboratories performing screening of multidrug resistant gramnegative rods (e.g. CPE, ESBL, MDR <i>Acinetobacter</i> and <i>P. aeruginosa</i>) by culture and/or direct nucleic acid detection method.			
5071 Surveillance for multidrug resistant bacteria, MRSA	1	1 2 3 4 5 6 7 8 9 10 11 12	
Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.			
Examinations: The scheme is intended for laboratories performing screening of MRSA (methicillin resistant <i>Staphylococcus aureus</i>) by culture and/or direct nucleic acid detection method.			
5072 Surveillance for multidrug resistant bacteria, VRE	1	1 2 3 4 5 6 7 8 9 10 11 12	
Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.			
Examinations: The scheme is intended for laboratories performing screening of VRE (vancomycin-resistant enterococci) by culture and/or direct nucleic acid detection method.			
5140 Throat streptococcal culture	1	1 2 3 4 5 6 7 8 9 10 11 12	
Specimens: 3 lyophilised mixtures of bacteria.			
Examinations: Culture and identification of group A, C and G streptococci.			
5060 Urine culture, quantitative screening	1	1 2 3 4 5 6 7 8 9 10 11 12	EQA ³
Specimens: 2 lyophilised samples and dilutor. Brief case histories also given. Pre- and/or post-analytical cases in part of the rounds.			
Examinations: Culture and quantitation, pre-and/or post-analytical indicators.			
Notes: Scheme 3170 available for urine bacterial screening with automated analysers.			

5065	Urine culture, quantitative screening, identification and susceptibility	1	1	2	3	4	5	6	7	8	9	10	11	12
------	--	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 lyophilised samples and dilutor. Brief case histories also given. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Pre- and/or post-analytical cases in part of the rounds.

Examinations: Culture, quantitation, identification and antimicrobial susceptibility testing, pre-and/or post-analytical indicators.

Notes: Scheme 3170 available for urine bacterial screening with automated analysers.

Microbiology » Mycology

5261	Fungal infections, nucleic acid detection	1	1	2	3	4	5	6	7	8	9	10	11	12
------	---	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 3-4 simulated samples. The samples may include yeasts, dermatophytes and moulds.

Examinations: Nucleic acid detection according to laboratory's own test selection.

Notes: Test selection of the participating lab is taken into consideration in result processing. The samples contain hDNA.

5260	Fungal culture	1	1	2	3	4	5	6	7	8	9	10	11	12
------	----------------	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 3 lyophilised samples. Brief case histories also given. The samples include moulds, dermatophytes and yeasts.

Examinations: Culture and identification. Antimicrobial susceptibility testing of yeast strains.

Microbiology » Parasitology

5472	Faecal parasites multiplex, nucleic acid detection	1	1	2	3	4	5	6	7	8	9	10	11	12
------	--	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 3 lyophilised samples.

Examinations: Nucleic acid detection of *Cryptosporidium*, *Dientamoeba fragilis*, *Entamoeba histolytica* and *Giardia lamblia*.

5430	Malaria, antigen and nucleic acid detection	3	1	2	3	4	5	6	7	8	9	10	11	12
------	---	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 3 whole blood samples. The scheme contains primarily *Plasmodium falciparum* positive and negative samples, occasionally other *Plasmodium* species are included.

Examinations: Antigen and nucleic acid detection. Target antigens: HRP2 and/or pLDH and/or aldolase.

Notes: For clinical laboratories and POCT sites.

5462	Malaria screening, Giemsa stain	3	1	2	3	4	5	6	7	8	9	10	11	12
------	---------------------------------	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.

Examinations: Preliminary screening of malaria plasmodia.

5463	Malaria screening, MGG stain	3	1	2	3	4	5	6	7	8	9	10	11	12
------	------------------------------	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.

Examinations: Preliminary screening of malaria plasmodia.

5460	Parasites in blood, Giemsa stain	3	1	2	3	4	5	6	7	8	9	10	11	12
------	----------------------------------	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.

Examinations: Screening and identification of malaria plasmodia and other blood parasites.

5470	Parasites in blood, Giemsa stain, virtual microscopy	5	1	2	3	4	5	6	7	8	9	10	11	12
------	--	---	---	---	---	---	---	---	---	---	---	----	----	----

Specimens: 2 virtual whole slide images of Giemsa stained smears prepared by using a scanner microscope. Brief case histories also given.

Examinations: Screening and identification of malaria plasmodia and other blood parasites.

5461 Parasites in blood, MGG stain	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.	Examinations: Screening and identification of malaria plasmodia and other blood parasites.	

5471 Parasites in blood, MGG stain, virtual microscopy	(5)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: 2 virtual whole slide images of MGG stained smears prepared by using a scanner microscope. Brief case histories also given.	Examinations: Screening and identification of malaria plasmodia and other blood parasites.	

5440 Parasites in faeces	(1)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: 3 stool samples in formalin. Brief case histories also given.	Examinations: Screening and identification of intestinal parasites (ova and parasites).	

5450 Parasites in faeces, virtual microscopy	(5)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: Virtual whole slide images of stool samples in formalin prepared by using a scanner microscope. Brief case histories also given.	Examinations: Screening and identification of intestinal parasites (ova and parasites).	

5420 Toxoplasma, antibodies	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: 3 liquid human plasma samples, 0.7 mL each. Brief case histories also given. Authentic commutable samples: Each sample batch originates from a single human donor.	Examinations: Toxoplasma IgG, IgM and total antibodies, IgG avidity, post-analytical clinical interpretation.	

5473 Trichomonas vaginalis, detection	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: 3 simulated samples.	Notes: The samples contain hDNA.	

EQA³

POCT

5651 CMV and EBV, nucleic acid detection, quantitative	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: 5 samples simulating plasma, 1.5 mL. Examinations: CMV and EBV NAT (quantitative).	Notes: Quantitative result processing.	

5650 Cytomegalovirus, antibodies	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: 3 liquid human plasma samples, 0.7 mL. Authentic commutable samples: each batch originates from a single human donor.	Examinations: Cytomegalovirus IgG, IgM and total antibodies, IgG avidity and post-analytical clinical interpretation.	

EQA³

5635 Dengue virus, antibodies and antigen detection	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens: 3 human serum or plasma samples, 0.5 mL. Authentic, commutable samples from a single human donor or occasionally simulated samples.	Examinations: Dengue virus IgG and IgM antibodies, Dengue virus antigen (NS1) and post-analytical clinical interpretation.	

POCT

EQA³

POCT	5640 EBV mononucleosis, POCT	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.		Examinations: MonAb. Notes: For clinical laboratories and POCT sites.											
EQA ³	5641 EBV mononucleosis, specific antibodies	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma samples, 1.4 mL. Authentic commutable samples: each batch originates from a single human donor.		Examinations: EBNA AbG, EBV VCA AbG, EBV VCA AbM, IgG Avidity and post-analytical clinical interpretation.											
EQA ³	5092 Hepatitis A, antibodies	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma samples, 0.6 mL. Authentic commutable samples: each batch originates from a single human donor.		Examinations: HAVAb, HAVAbM, HAVAbG and post-analytical clinical interpretation.											
EQA ³	5094-5096 Hepatitis B and C, serology, specimen volume 0.6 mL / 1.2 mL / 2.0 mL	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma samples, 0.6 / 1.2 / 2.0 mL. Authentic commutable samples: each batch originates from a single human donor. Examinations: HBsAg, HBsAgCt, HBcAb, HBcAbM, HBeAb, HBeAg, HBsAb (qual), HCVAb, HCVAbCt, and post-analytical clinical interpretation.		Volume specific product codes: 5094: for 0.6 mL human plasma specimens 5095: for 1.2 mL human plasma specimens 5096: for 2.0 mL human plasma specimens Notes: For clinical laboratories. Scheme 5687 is for POCT users.											
POCT NEW	5687 HBsAg and HCVAb POCT	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma samples, 0.5 mL. Examinations: HBsAg, HCVAb POCT.		Notes: This scheme is only for POC tests. Scheme 5094-5096 is for clinical laboratories.											
EQA ³	5093 Hepatitis B, s-antigen antibodies, quantitative	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 2 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.		Examinations: HBsAb (anti-HBs), quantitative.											
EQA ³	5679 Hepatitis B virus, nucleic acid detection (DNA)	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 lyophilised or liquid plasma samples, 1.2 mL.		Examinations: HBV DNA, quantitative and/or qualitative nucleic acid detection.											
EQA ³	5678 Hepatitis C virus, nucleic acid detection (RNA)	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 lyophilised or liquid plasma samples, 1.2 mL.		Examinations: HCV RNA, quantitative and/or qualitative nucleic acid detection.											
EQA ³	5682 Hepatitis E, antibodies	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.		Examinations: Hepatitis E virus IgG and IgM antibodies, post-analytical clinical interpretation.											
EQA ³	5555 Herpes simplex 1 and 2, antibodies	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor. Occasionally simulated samples.		Examinations: HSV IgG (qualitative/quantitative), HSV IgM, HSV-1 IgG, HSV-2 IgG.											

5680 HIV-1, nucleic acid detection (RNA)	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 lyophilised or liquid plasma samples, 1.2 mL.	

5091 HIV, antibodies and antigen detection	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 liquid human plasma samples, 0.7 mL.	
Examinations:	HIVAb (1/2), HIVAgAb (combo), HIVAg (p24), HIVAb confirmatory test and post-analytical clinical interpretation. Positive specimens may include HIV-1 or HIV-2.	

5088 HIV, antibodies and antigen detection, extra set of samples		1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 liquid human plasma samples, 0.7 mL.	

5090 HIV, antibodies and antigen detection, POCT	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 liquid human plasma samples, 0.5 mL.	
Examinations:	HIVAb and HIVAgAb (combo) POCT.	

5556 HSV1&2/VZV/Treponema pallidum, nucleic acid detection	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 samples simulating swab samples taken from lesions.	
Examinations:	Nucleic acid detection of HSV1, HSV2, VZV, <i>Treponema pallidum</i> .	

5086 Human papillomavirus, nucleic acid detection	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	2 simulated samples, 1 mL.	
Examinations:	High-risk human papillomavirus NAT (hrHPVNAT). HPV genotypes included are: 16, 18, 31, 33, 39, 45, 51, 52, 66, 67.	

5089 Human T-cell lymphotropic virus, antibodies	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	
Examinations:	HTLVAb screening and confirmatory tests, post-analytical clinical interpretation. Positive samples may include HTLV-1 or HTLV-2.	

5670 Influenza virus A+B and RS virus, nucleic acid detection	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 simulated liquid samples, 1 mL.	
Examinations:	InfANAT, InfBNAT, RSVNAT.	

5671 Influenza virus A+B, antigen detection	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 liquid and/or swab samples.	
Examinations:	InfAAg, InfBAg.	

5668 Measles virus, antibodies	(3)	1 2 3 4 5 6 7 8 9 10 11 12
Specimens:	3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor.	
Examinations:	Measles virus IgG and IgM antibodies and post-analytical clinical interpretation.	

EQAS ³	5562 Multiple respiratory virus, nucleic acid detection	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 simulated swab samples. Examinations: Influenza A/B virus NAT, RSV NAT and SARS-CoV-2 NAT.													
POCT NEW	5669 Mumps virus, antibodies	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor. Examinations: Mumps virus IgG and IgM antibodies and post-analytical clinical interpretation.													
POCT	5683 Mpox (Monkeypox virus), nucleic acid detection	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 2 swab samples simulating patient samples from lesions. Examinations: Mpox NAT.													
POCT NEW	5686 Norovirus, antigen detection	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 simulated swab samples. Examinations: Norovirus antigen detection, genogroups GI and GII.													
POCT	5675 Norovirus, nucleic acid detection	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 simulated samples, 1 mL. Examinations: Norovirus NAT, genogroups GI and GII.													
POCT EQAS ³	5660 Parvovirus B19, antibodies	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma or serum samples, 0.4 mL. Authentic commutable samples: each batch originates from a single human donor. Examinations: Parvovirus IgG, IgM, IgG avidity and post-analytical clinical interpretation.													
POCT EQAS ³	5560 Puumala virus, antibodies	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid human plasma or serum samples, 0.3 mL. Brief case histories are also provided. Examinations: Puumala virus IgG, IgM, POC tests and specific antibodies, IgG avidity and post-analytical clinical interpretation. Notes: For clinical laboratories and POCT sites.													
POCT	5673 Respiratory adenovirus, antigen detection	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 simulated samples, 1 mL. Examinations: Adenovirus Ag.													
POCT	5098 Rotavirus and adenovirus, antigen detection	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 artificial faecal samples. Examinations: Rotavirus and adenovirus antigen detection.													
POCT	5672 RS virus, antigen detection	(3)	1	2	3	4	5	6	7	8	9	10	11	12
	Specimens: 3 liquid and/or swab samples. Examinations: RSVAg.													
Notes: For clinical laboratories and POCT sites. This scheme is only for antigen detection methods.														

5667 Rubella virus, antibodies														EQA ³		
		Specimens: 3 liquid human plasma samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor. Examinations: Rubella virus IgG and IgM antibodies, IgG avidity and post-analytical clinical interpretation.														
5677 SARS-CoV-2, antibodies															POCT	
			Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor. Examinations: SARS-CoV-2 Ab, SARS-CoV-2 IgG, SARS-CoV-2 IgM, SARS-CoV-2 IgA. Notes: For clinical laboratories and POCT sites.													
5681 SARS-CoV-2, antigen detection															POCT	
			Specimens: 3 simulated samples. Examinations: SARS-CoV-2 Ag. Notes: For clinical laboratories and POCT sites.													
5676 SARS-CoV-2, nucleic acid detection															POCT	
			Specimens: 3 simulated whole genome cDNA samples. Examinations: SARS-CoV-2 NAT. Notes: Including variants. Scheme is not suitable for TMA methods (e.g. Hologic Aptima SARS-CoV-2 Assay). The samples contain hDNA.													
5099 Tick-borne encephalitis virus, antibodies															EQA ³ POCT	
			Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor. Examinations: TBE IgG, IgM, total antibodies and post-analytical clinical interpretation. Notes: For clinical laboratories and POCT sites.													
5665 Varicella zoster virus, antibodies															EQA ³	
			Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Authentic commutable samples: each batch originates from a single human donor. Examinations: Varicella zoster IgG, IgM, total antibodies and post-analytical clinical interpretation.													
5636 Zika virus, antibodies															EQA ³	
			Specimens: 3 liquid human plasma or serum samples, 0.5 mL. Examinations: Zika virus IgG, Zika virus IgM, clinical interpretation.													

Multiplex

Multiplex EQA schemes are aimed to support laboratories to fulfill quality requirements of multiplex nucleic acid tests. All schemes include clinically relevant samples specially designed for multiplex nucleic acid testing. The multiplex schemes are annual programs and during the period of one calendar year, a comprehensive selection of listed pathogens will be covered.

5100 Blood culture (incl. sepsis multiplex methods)		1 2 3 4 5 6 7 8 9 10 11 12															
		Specimens:	3 lyophilized samples. Brief case histories also given. Fresh blood is needed in the specimen preparation. The samples intended for susceptibility testing may include both international quality control strains and clinical strains.	Examinations:	Culture, identification, antimicrobial susceptibility testing. Direct nucleic acid detection from positive blood culture bottles by multiplex methods is included in the scheme.	Notes:	Fresh blood is needed but not included in the shipment.	1	2	3	4	5	6	7	8	9	10
5101 Blood culture, screening (incl. sepsis multiplex methods)		1	2	3	4	5	6	7	8	9	10	11	12				
Specimens:	3 lyophilized samples. Brief case histories also given. Fresh blood is needed in the specimen preparation.	Examinations:	Culture, preliminary identification using Gram staining and/or direct nucleic acid detection from positive blood culture bottles by multiplex methods. The scheme is also suitable for stem cell banks screening only for possible growth.	Notes:	Fresh blood is needed but not included in the shipment.	1	2	3	4	5	6	7	8	9	10	11	12
5191 Faecal bacterial pathogens multiplex, nucleic acid detection		1	2	3	4	5	6	7	8	9	10	11	12				
Specimens:	3 samples. Either lyophilized mixtures of bacteria and/or simulated samples, 1 mL.	Examinations:	EIEC, <i>E. coli</i> EPEC, <i>E. coli</i> ETEC, <i>Plesiomonas</i> , <i>Salmonella</i> , <i>Shigella</i> and <i>Yersinia</i> .	Notes:	During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.	1	2	3	4	5	6	7	8	9	10	11	12
5472 Faecal parasites multiplex, nucleic acid detection		1	2	3	4	5	6	7	8	9	10	11	12				
Specimens:	3 lyophilized samples.	Examinations:	Nucleic acid detection of <i>Cryptosporidium</i> , <i>Dientamoeba fragilis</i> , <i>Entamoeba histolytica</i> , <i>Giardia lamblia</i> .	1	2	3	4	5	6	7	8	9	10	11	12		
5304 Gastrointestinal viral multiplex, nucleic acid detection		1	2	3	4	5	6	7	8	9	10	11	12				
Specimens:	3 simulated samples, 1 mL.	Examinations:	Direct multiplex nucleic acid detection. Pathogens included are: Adenovirus, Astrovirus, Norovirus, Rotavirus, Sapovirus.	Notes:	During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.	1	2	3	4	5	6	7	8	9	10	11	12
5303 Meningitis-encephalitis multiplex, nucleic acid detection		1	2	3	4	5	6	7	8	9	10	11	12				
Specimens:	3 simulated samples, 1 mL.	Examinations:	Direct multiplex nucleic acid detection. Pathogens included are <i>Escherichia coli</i> K1, <i>Haemophilus influenzae</i> , <i>Listeria monocytogenes</i> , <i>Neisseria meningitidis</i> , <i>Streptococcus agalactiae</i> , <i>Streptococcus pneumoniae</i> , Cytomegalovirus (CMV), Enterovirus, Epstein-Barr virus (EBV), Herpes simplex virus 1 (HSV1), Herpes simplex virus 2 (HSV2), Human herpesvirus 6 (HHV6), Human parechovirus (HPeV), Varicella zoster virus (VZV) <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> .	Notes:	During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.	1	2	3	4	5	6	7	8	9	10	11	12
5300 Respiratory infections multiplex, nucleic acid detection		1	2	3	4	5	6	7	8	9	10	11	12				
Specimens:	4 simulated samples, 1 mL.	Examinations:	Direct multiplex nucleic acid detection. Pathogens included are adenovirus, bocavirus, <i>B. parapertussis</i> , <i>B. pertussis</i> , <i>C. pneumoniae</i> , coronavirus (OC43, 229E, NL63, HKU1), enterovirus, influenza virus A/B, <i>L. pneumophila</i> , metapneumovirus, <i>M. pneumoniae</i> , parainfluenzavirus 1-4, rhinovirus, RSV A/B, SARS-CoV-2 and <i>S. pneumoniae</i> .	Notes:	During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. The samples contain hDNA.	1	2	3	4	5	6	7	8	9	10	11	12
5302 Sexually transmitted diseases multiplex, nucleic acid detection		1	2	3	4	5	6	7	8	9	10	11	12				
Specimens:	4 simulated swab/urine samples, 2 mL.	Examinations:	<i>C. trachomatis</i> , <i>M. genitalium</i> , <i>M. hominis</i> , <i>N. gonorrhoeae</i> , <i>T. vaginalis</i> , <i>U. parvum</i> and <i>U. urealyticum</i> .	Notes:	During the period of one calendar year, a comprehensive selection of listed pathogens will be covered. The samples contain hDNA.	1	2	3	4	5	6	7	8	9	10	11	12

EQAs including Antimicrobial Susceptibility Testing

Bacteriology and mycology

- 5100 Blood culture
- 5190 Faecal culture (rounds 2 and 4)
- 5260 Fungal culture
- 5080 General Bacteriology 1
- 5081 General Bacteriology 2
- 5253 *Helicobacter pylori*, drug resistance, nucleic acid detection
- 5230 *Mycobacterium tuberculosis*, drug resistance, nucleic acid detection

- 5254 *Mycoplasma genitalium*, drug resistance, nucleic acid detection
- 5120 *Neisseria gonorrhoeae* (Gc), culture and susceptibility testing
- 5073 Surveillance for multidrug resistant bacteria, gramnegative rods
- 5071 Surveillance for multidrug resistant bacteria, MRSA
- 5072 Surveillance for multidrug resistant bacteria, VRE
- 5065 Urine culture, quantitative screening, identification and susceptibility

EQAs suitable for direct nucleic acid testing methods

Bacteriology

- 5612 *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, nucleic acid detection
- 5201 *Clostridioides difficile*, nucleic acid detection
- 5191 Faecal bacterial pathogens multiplex, nucleic acid detection
- 5253 *Helicobacter pylori*, drug resistance, nucleic acid detection
- 5221 Mycobacterial nucleic acid detection
- 5230 *Mycobacterium tuberculosis*, drug resistance, nucleic acid detection
- 5254 *Mycoplasma genitalium*, drug resistance, nucleic acid detection
- 5599 *Streptococcus agalactiae* (GBS), nucleic acid detection
- 5593 *Streptococcus pyogenes* (Group A), nucleic acid detection in pharyngeal sample
- 5071 Surveillance for multidrug resistant bacteria, MRSA
- 5072 Surveillance for multidrug resistant bacteria, VRE
- 5073 Surveillance for multidrug resistant bacteria, gramnegative rods

Multiplex

- 5191 Faecal bacterial pathogens multiplex, nucleic acid detection
- 5472 Faecal parasites multiplex, nucleic acid detection
- 5304 Gastrointestinal viral multiplex, nucleic acid detection
- 5303 Meningitis-encephalitis multiplex, nucleic acid detection
- 5300 Respiratory infections multiplex, nucleic acid detection
- 5302 Sexually transmitted diseases multiplex, nucleic acid detection

Parasitology

- 5472 Faecal parasites multiplex, nucleic acid detection
- 5430 Malaria, antigen and nucleic acid detection
- 5473 *Trichomonas vaginalis*, detection

Virology

- 5651 CMV and EBV, nucleic acid detection, quantitative
- 5679 Hepatitis B virus, nucleic acid detection (DNA)
- 5678 Hepatitis C virus, nucleic acid detection (RNA)
- 5680 HIV-1, nucleic acid detection (RNA)
- 5556 HSV1&2/VZV/*Treponema pallidum*, nucleic acid detection
- 5086 Human papillomavirus, nucleic acid detection
- 5670 Influenza virus A+B and RS virus, nucleic acid detection
- 5562 Multiple Respiratory Virus, nucleic acid detection
- 5683 Mopox (Monkeypox virus), nucleic acid detection
- 5675 Norovirus, nucleic acid detection
- 5676 SARS-CoV-2, nucleic acid detection

Mycology

- 5261 Fungal infections, nucleic acid detection

EQA services for POCT sites

Patient outcome is associated with obtaining a reliable test result regardless of where the testing is performed. To ensure high quality of care and patient safety, it is imperative that point-of-care testing (POCT) is subjected to the same quality requirements as conventional laboratory analyses.

Labquality offers a range of EQA schemes suitable for POCT sites. These services are intended for all testing units including home/community nursing, hospital wards, pediatric clinics, surgical units, occupational healthcare, outpatient clinics and medical centers.

Microbiology

5635 Dengue virus, antibodies and antigen detection

5640 EBV mononucleosis, POCT

5860 *Helicobacter pylori*, antibodies

5596 *Helicobacter pylori*, antigen detection in faeces

5090 HIV, antibodies and antigen detection, POCT

5687 HBsAg and HCVAb POCT

5671 Influenza virus A+B, antigen detection

5597 Legionella, antigen detection in urine

5430 Malaria, antigen and nucleic acid detection

5980 *Mycoplasma pneumoniae*, antibodies

5686 Norovirus, antigen detection

5560 Puumala virus, antibodies

5673 Respiratory adenovirus, antigen detection

5098 Rotavirus and adenovirus, antigen detection

5672 RS virus, antigen detection

5677 SARS CoV-2, antibodies

5681 SARS-CoV-2 antigen detection

5676 SARS-CoV-2 nucleic acid detection

5595 *Streptococcus pyogenes*, group A,
antigen detection in pharyngeal sample

5599 *Streptococcus agalactiae* (GBS), nucleic acid detection

5598 *Streptococcus pneumoniae*, antigen detection in urine

5099 Tick-borne encephalitis virus, antibodies

5473 *Trichomonas vaginalis*, detection

LABQUALITY



**We are
Quality Makers**